Combination Therapy Of Intra-arterial 5-fluorouracil And Systemic Pegylated Interferon α-2b For Advanced Hepatocellular Carcinoma | 3501
Journal of Gastrointestinal & Digestive System
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Two recent phase III clinical trials have shown that sorafenib, an orally available multikinase inhibitor, improves
the median overall survival in patients with advanced hepatocellular carcinoma (HCC). However, patients with HCC and portal
vein tumor thrombosis (PVTT) usually have very short survival and grave prognosis even when treated with sorafenib. On the
other hand, recent advances in implantable drug delivery systems have made it possible to administer repeated arterial infusion of
chemotherapy agent. Compared with systemic chemotherapy, hepatic arterial infusion chemotherapy (HAIC) has the benefits of
increasing the local concentration of drugs and reducing systemic side effects. Since 2006, we have treated the patients displaying
advanced HCC with PVTT by combining HAIC of 5-fluorouracil (5-FU) and systemic pegylated interferon (PEG-IFN) α-2b,
and reported favorable results. In this article, we evaluated the efficacy of combined 5-FU and PEG-IFN α-2b, and compared
outcomes between advanced HCC patients with PVTT treated using sorafenib.
Forty patients with HCC and PVTT were enrolled. Of these, 21 patients were treated using subcutaneous administration
of PEG-IFN α-2b and intra-arterial infusion of 5-FU [5-FU/PEG-IFN group], 19 patients were treated using continuous oral
treatment with 400-800 mg of sorafenib (consisting of two 100-200 mg tablets) twice daily [Sorafenib group]. We compared the
early response to the therapy, progression free survival (PFS) and the cumulative survival rate between these two groups.
The objective early response rate in the 5-FU/PEG-IFN group was significantly higher than that in the Sorafenib group
(71.4 vs. 10.5%, P<0.01). The median PFS time of the 5-FU/PEG-IFN and the Sorafenib group were 10.9, and 2.8 months,
respectively. The cumulative survival rates at 6, 12, 18, and 24 months, respectively, were 83.8, 77.8, 55.6, and 55.6% in the 5FU/
PEG-IFN group, and 68.4, 37.7, 16.2, and 16.2% in the Sorafenib group. The cumulative survival rates was significantly higher
in the 5FU/PEG-IFN group than in the Sorafenib group (P=0.03). Serious complications and treatment-related deaths were not
observed in the 5FU/PEG-IFN group. On the other hand, the rate of discontinuation of treatment due to adverse events was
36.8% of the patients who were treated sorafenib.
Based on our findings, this newly developed combination therapy may be useful for patients with advanced HCC,
although a large-scale randomized controlled study by comparison with Sorafenib is needed to properly evaluate the efficacy of
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals